AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25218256 — intervention group
Group type: EXPERIMENTAL
Intervention: Real iTBS
Number of subjects: 72
Study 25218256 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 72
Study 25218544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid deployment aortic valve replacement using a stented trileaflet bovine pericardial bioprosthesis
Number of subjects: 287
Study 25218544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid deployment aortic valve replacement
Number of subjects: 287
Study 25219292 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase beta (0.5mg/kg/week) administered intravenously for 52 weeks
Number of subjects: 6
Study 25220020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delta-9-tetrahydrocannabinol (THC) treatments
Number of subjects: 11
Study 25220020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum cannabis smoking
Number of subjects: 11
Study 25220528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure variation (PPV)-guided fluid therapy
Number of subjects: 98
Study 25220528 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 98
Study 25220574 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous ascorbic acid (AA) at doses of 5, 30, and 60 g
Number of subjects: 10
Study 25221331 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED replacement with or without planned lead addition or revision
Number of subjects: 1744
Study 25221331 — intervention group
Group type: EXPERIMENTAL
Intervention: REPLACE DARE Score
Number of subjects: 1744
Study 25221331 — intervention group
Group type: EXPERIMENTAL
Intervention: DARE=0
Number of subjects: 1744
Study 25221331 — intervention group
Group type: EXPERIMENTAL
Intervention: DARE=7
Number of subjects: 1744
Study 25221331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard ratio for each change of 1 DARE unit
Number of subjects: 1744
Study 25221331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 1744
Study 25221331 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1744
Study 25221334 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional navigational model guided lead delivery for LV leads
Number of subjects: 31
Study 25221334 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional navigational model guided lead delivery for RV leads
Number of subjects: 31
Study 25221334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response criteria
Number of subjects: 31
Study 25221334 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 31
Study 25221606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2,000 I.U. daily for 12 weeks
Number of subjects: 0
Study 25221606 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25222119 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) prophylaxis for PMTCT or triple antiretroviral treatment in pregnancy
Number of subjects: 408
Study 25222119 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 408
Study 25222119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravidity
Number of subjects: 408
Study 25222119 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral regimen (adjusted for age and gravidity)
Number of subjects: 408
Study 25222119 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) or triple ARVs
Number of subjects: 408
Study 25222129 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoids (SCs) use in the last month
Number of subjects: 1080
Study 25222129 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with SC use
Number of subjects: 1080
Study 25222129 — intervention group
Group type: EXPERIMENTAL
Intervention: SC use before and after federal ban
Number of subjects: 1080
Study 25222841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline treatment
Number of subjects: 24
Study 25223394 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg) administered subcutaneously every other week
Number of subjects: 30
Study 25223394 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg loading dose of adalimumab
Number of subjects: 30
Study 25223501 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 9
Study 25223531 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-funded continuous glucose monitoring system (RT-CGMS)
Number of subjects: 149
Study 25223531 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring blood glucose (SMBG) only
Number of subjects: 149
Study 25223531 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-CGMS
Number of subjects: 149
Study 25224002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 95
Study 25224267 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune cell populations in psoriatic adipose tissue
Number of subjects: 30
Study 25224267 — intervention group
Group type: EXPERIMENTAL
Intervention: CD16+CD56(Lo) NK cell population
Number of subjects: 30
Study 25224611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock clinical trial (MCT) for adolescents (aged 15-17)
Number of subjects: 135
Study 25224611 — intervention group
Group type: COMPARATOR
Intervention: Mock clinical trial (MCT) for young adult women (aged 18-21)
Number of subjects: 135
Study 25224748 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time-to-process (less than 7 h)
Number of subjects: 22
Study 25224748 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter resting-time (less than 2 h)
Number of subjects: 22
Study 25224748 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer stimulation-time (overnight)
Number of subjects: 22
Study 25224748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood
Number of subjects: 22
Study 25224842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance testing (OGTT) with 300 ml of glucose-containing fluid
Number of subjects: 30
Study 25224842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance testing (MMTT) with 237 ml of fat/protein/carbohydrate-containing fluid
Number of subjects: 30
Study 25225206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioencapsulated ACE2
Number of subjects: 100
Study 25225206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioencapsulated Ang-(1-7)
Number of subjects: 100
Study 25225206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ACE2 and Ang-(1-7)
Number of subjects: 100
Study 25225206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioencapsulated ACE2 or Ang-(1-7) in reversal protocol
Number of subjects: 100
Study 25225420 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent carfilzomib (56 mg/m2)
Number of subjects: 55
Study 25225420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus low-dose dexamethasone (45 or 56 mg/m2)
Number of subjects: 55
Study 25225420 — intervention group
Group type: COMPARATOR
Intervention: Single-agent carfilzomib (70 mg/m2)
Number of subjects: 55
Study 25225420 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent carfilzomib (20 to 56 mg/m2)
Number of subjects: 55
Study 25225420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (various doses)
Number of subjects: 55
Study 25225437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg
Number of subjects: 144
Study 25225437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg
Number of subjects: 144
Study 25225676 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccines (4 mg administered intramuscularly by Biojector at weeks 0, 4, and 8, with a homologous boost at or after week 32)
Number of subjects: 0
Study 25225676 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccines (4 mg administered intramuscularly by Biojector)
Number of subjects: 0
Study 25225676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth DNA vaccination
Number of subjects: 0
Study 25225962 — intervention group
Group type: EXPERIMENTAL
Intervention: NaviAid G-EYE balloon-colonoscope
Number of subjects: 47
Study 25226293 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous kisspeptin (0.24 nmol/kg) administered intravenously
Number of subjects: 12
Study 25226293 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (75 ng/kg) administered intravenously
Number of subjects: 12
Study 25226293 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous GnRH (25 ng/kg sc every 2 h for six days)
Number of subjects: 12
Study 25226407 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g ethanol
Number of subjects: 12
Study 25226407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25226426 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 39
Study 25227179 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat diet + 3.45 g/d of docosahexaenoic acid (DHA) for 8 weeks
Number of subjects: 23
Study 25227334 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-msec light flashes given every 30 sec during sleep (n = 6)
Number of subjects: 13
Study 25227334 — intervention group
Group type: COMPARATOR
Intervention: Darkness (control group, n = 7)
Number of subjects: 13
Study 25227476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (a thiazolidinedione)
Number of subjects: 0
Study 25227629 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a history of or current anogenital warts (AGW)
Number of subjects: 600
Study 25227629 — intervention group
Group type: COMPARATOR
Intervention: Participants with no history of anogenital warts (AGW)
Number of subjects: 600
Study 25228283 — intervention group
Group type: EXPERIMENTAL
Intervention: Draf IIa frontal sinus surgery
Number of subjects: 63
Study 25228850 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 94
Study 25228850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 25229334 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnt sugarcane harvesting
Number of subjects: 28
Study 25230375 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation-plus-extracorporeal CO2 removal
Number of subjects: 46
Study 25230375 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation-only
Number of subjects: 46
Study 25230939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap5 (Adacel) vaccine administered to 10-year-olds
Number of subjects: 1291
Study 25231271 — intervention group
Group type: EXPERIMENTAL
Intervention: InTEM test
Number of subjects: 148
Study 25231271 — intervention group
Group type: COMPARATOR
Intervention: ACT measurement
Number of subjects: 148
Study 25232260 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-mycotic therapy based on the developed algorithm
Number of subjects: 127
Study 25232260 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Candida species in bile samples
Number of subjects: 127
Study 25232260 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors for biliary candidiasis
Number of subjects: 127
Study 25232260 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of azole-resistant Candida subspecies
Number of subjects: 127
Study 25232828 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Number of subjects: 23
Study 25232828 — intervention group
Group type: COMPARATOR
Intervention: Historical outcomes in unselected patients
Number of subjects: 23
Study 25233155 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 1532
Study 25233248 — intervention group
Group type: COMPARATOR
Intervention: qEEG ratio of delta to alpha frequency power
Number of subjects: 385
Study 25233248 — intervention group
Group type: COMPARATOR
Intervention: qEEG ratio
Number of subjects: 385
Study 25233248 — intervention group
Group type: COMPARATOR
Intervention: qEEG ratio ≤10.5 among patients not taking benzodiazepines
Number of subjects: 385
Study 25233248 — intervention group
Group type: COMPARATOR
Intervention: Routine PSG measures
Number of subjects: 385
Study 25233248 — intervention group
Group type: COMPARATOR
Intervention: Obstructive sleep apnea
Number of subjects: 385
Study 25233297 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4
Number of subjects: 38
Study 25233297 — intervention group
Group type: COMPARATOR
Intervention: Enlite
Number of subjects: 38
Study 25234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 3 Gy (n=3)
Number of subjects: 14
Study 25234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 6 Gy (n=3)
Number of subjects: 14
Study 25234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 9 Gy (n=6)
Number of subjects: 14
Study 25234438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated total marrow irradiation (TMI) at 12 Gy (n=2)
Number of subjects: 14
Study 25234476 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients with dysphagia
Number of subjects: 74
Study 25234476 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients without dysphagia
Number of subjects: 74
Study 25234476 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 74
Study 25234476 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 74
Study 25234476 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of dysphagia
Number of subjects: 74
Study 25234930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m2 at first infusion and 250 mg/m2 subsequently) combined with cisplatin (80 mg/m2, triweekly) and capecitabine (2,000 mg/m2, triweekly for 2 weeks)
Number of subjects: 47
Study 25234930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with cisplatin and capecitabine
Number of subjects: 47
Study 25236503 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Ms (Medication, Meter, and Meals) intervention
Number of subjects: 5
Study 25236513 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR markers of myocardial damage (Infarct Size - IS, Microvascular Obstruction - MO)
Number of subjects: 738
Study 25236513 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR markers of myocardial damage (IS and MO)
Number of subjects: 738
Study 25236780 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 342
Study 25236780 — intervention group
Group type: COMPARATOR
Intervention: Ongoing medical management
Number of subjects: 342
Study 25236899 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachway assistance with a preformed nasotracheal tube
Number of subjects: 0
Study 25236916 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20 (subcutaneous immunoglobulin)
Number of subjects: 24
Study 25236916 — intervention group
Group type: COMPARATOR
Intervention: IVIG (intravenous immunoglobulin)
Number of subjects: 24
Study 25236917 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily (n = 122)
Number of subjects: 202
Study 25236917 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 80)
Number of subjects: 202
Study 25236917 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (without sulfonylureas)
Number of subjects: 202
Study 25236982 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavituximab plus paclitaxel and carboplatin
Number of subjects: 49
Study 25237810 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 25237810 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25238535 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN α-2a plus ribavirin
Number of subjects: 2347
Study 25238535 — intervention group
Group type: COMPARATOR
Intervention: Genotype 2
Number of subjects: 2347
Study 25238535 — intervention group
Group type: COMPARATOR
Intervention: Genotype 3
Number of subjects: 2347
Study 25239224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus-trastuzumab
Number of subjects: 34
Study 25239228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily after HSCT for 12 cycles (28 days each).
Number of subjects: 22
Study 25239440 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Granulomatous Disease (CGD) patients
Number of subjects: 41
Study 25239440 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 41
Study 25239610 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 60 mg QOD
Number of subjects: 71
Study 25239610 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 200 mg QW
Number of subjects: 71
Study 25240075 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 437
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lipid-rich necrotic core (LRNC)
Number of subjects: 303
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevalence among adults with LRNC
Number of subjects: 303
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean percent lumen area
Number of subjects: 303
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized mean wall area
Number of subjects: 303
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum wall area
Number of subjects: 303
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent lumen area in cross-sectional images with LRNC
Number of subjects: 303
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized mean wall thickness in cross-sectional images with LRNC
Number of subjects: 303
Study 25240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized maximum wall thickness in cross-sectional images with LRNC
Number of subjects: 303
Study 25240453 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 1039
Study 25240453 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1039
Study 25240453 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment LDL-C levels <70 mg/dl
Number of subjects: 1039
Study 25240453 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment LDL-C levels ≥70 mg/dl
Number of subjects: 1039
Study 25240525 — intervention group
Group type: EXPERIMENTAL
Intervention: REPAIR group (standardized aortic valve repair technique with expansible aortic ring annuloplasty)
Number of subjects: 261
Study 25240525 — intervention group
Group type: COMPARATOR
Intervention: CVG group (mechanical composite valve and graft replacement)
Number of subjects: 261
Study 25240540 — intervention group
Group type: EXPERIMENTAL
Intervention: Late/very late DES thrombosis cases
Number of subjects: 492
Study 25241909 — intervention group
Group type: EXPERIMENTAL
Intervention: CB COPD
Number of subjects: 3
Study 25241933 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin clearance (PCT-c) measured at diagnosis, 24 hours, and 48 hours
Number of subjects: 130
Study 25241933 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ Sequential Organ Failure Assessment (SOFA) score measured at ICU admission and after 48 hours
Number of subjects: 130
Study 25242374 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly doses)
Number of subjects: 12
Study 25242374 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m(2)) with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg tri-weekly doses)
Number of subjects: 12
Study 25242417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) with 9 months of leuprolide and flutamide followed by off-treatment interval.
Number of subjects: 0
Study 25242417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) with longer time (≥ 60 days) to PSA rise after rise to T > 50 ng/dL.
Number of subjects: 0
Study 25242417 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first T > 50 ng/dL and PSA doubling time.
Number of subjects: 0
Study 25242417 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned.
Number of subjects: 0
Study 25242443 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred contact method (text messaging, e-mail, or any)
Number of subjects: 542
Study 25242443 — intervention group
Group type: COMPARATOR
Intervention: Landline phone as contact method
Number of subjects: 542
Study 25242443 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred contact other than phone
Number of subjects: 542
Study 25242443 — intervention group
Group type: COMPARATOR
Intervention: Having a landline phone
Number of subjects: 542
Study 25242890 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus SPC enriched with a standardized psychological intervention for patients and caregivers at home
Number of subjects: 340
Study 25242890 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 340
Study 25243015 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for STIs (Chlamydia trachomatis, Neisseria gonorrhea, syphilis, Trichomonas vaginalis)
Number of subjects: 2293
Study 25243015 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident STIs over a 24 month period
Number of subjects: 2293
Study 25243015 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for incident STIs
Number of subjects: 2293
Study 25243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered decision support notifications delivered via a personalized health record (PHR)
Number of subjects: 584
Study 25243446 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of CMV-seronegative and leukoreduced blood
Number of subjects: 539
Study 25243446 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal breast milk feeding
Number of subjects: 539
Study 25243564 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal peritoneum (PP) used as an autologous substitute for venous reconstruction during HPB surgery.
Number of subjects: 30
Study 25243573 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care intervention
Number of subjects: 2017